http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3212220-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd2d839f6ef5f0882919e7d1f6442cfc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2015-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e272eb79128d8dee8902e16cf974aeaa |
| publicationDate | 2017-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3212220-A1 |
| titleOfInvention | Inflammatory disease |
| abstract | The present invention is directed to alpha-MSH analogues for treatment of inflammatory disease. |
| priorityDate | 2014-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.